Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P17174 (
aspartate aminotransferase
)
14,872
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Toxoplasma gondii
is an obligate intracellular protozoan parasite and a successful parasitic pathogen in diverse organisms and host cell types. Hydroxylamine (HYD) and carboxymethoxylamine (CAR) have been reported as inhibitors of aspartate aminotransferases (AATs) and interfere with the proliferation in
Plasmodium falciparum
Therefore, AATs are suggested as drug targets against
Plasmodium
The
T. gondii
genome encodes only one predicted
AAT
in both
T. gondii
type I strain RH and type II strain
PLK
. However, the effects of HYD and CAR, as well as their relationship with
AAT
, on
T. gondii
remain unclear. In this study, we found that HYD and CAR impaired the lytic cycle of
T. gondii
in vitro
, including the inhibition of invasion or reinvasion, intracellular replication, and egress. Importantly, HYD and CAR could control acute toxoplasmosis
in vivo
Further studies showed that HYD and CAR could inhibit the transamination activity of r
Tg
AAT
in vitro
However, our results confirmed that deficiency of
AAT
in both RH and
PLK
did not reduce the virulence in mice, although the growth ability of the parasites was affected
in vitro
HYD and CAR could still inhibit the growth of
AAT
-deficient parasites. These findings indicated that HYD and CAR inhibition of
T. gondii
growth and control of toxoplasmosis can occur in an
AAT
-independent pathway. Overall, further studies focusing on the elucidation of the mechanism of inhibition are warranted. Our study hints at new substrates of HYD and CAR as potential drug targets to inhibit
T. gondii
growth.
...
PMID:Hydroxylamine and Carboxymethoxylamine Can Inhibit
Toxoplasma gondii
Growth through an Aspartate Aminotransferase-Independent Pathway. 3190 78